<DOC>
	<DOCNO>NCT00003797</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness gemcitabine trastuzumab treat patient metastatic cancer pancreas overexpresses HER2/neu .</brief_summary>
	<brief_title>Gemcitabine Monoclonal Antibody Therapy Treating Patients With Metastatic Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate survival patient metastatic pancreatic cancer overexpression HER2/neu treat gemcitabine trastuzumab . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute weekly week 1-7 . Patients receive trastuzumab IV 90 minute week 1 trastuzumab IV 30-90 minute weekly week 2-8 . Patients stable respond disease receive gemcitabine IV 30 minute weekly week 1-3 trastuzumab IV 30 minute weekly week 1-4 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A maximum 41 patient accrue study 18-24 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic pancreatic cancer overexpression HER2/neu Patients inadequate tissue evaluate HER2/neu overexpression elevate serum HER2/neu antigen level eligible Radiographically measurable disease May metastatic disease primary lesion measurable metastatic lesion measurable Ascites measurable PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 3.0 mg/dL Greater 3 time normal increase bilirubin due biliary obstruction tumor long biliary system stented bypassed bilirubin , SGOT , SGPT stable decrease SGOT great 3 time normal No great 5 time normal liver metastasis present OR Greater 5 time normal increase SGOT SGPT due biliary obstruction tumor long biliary system stented bypassed biliary SGOT SGPT stable decrease Renal : Creatinine great 2.0 mg/dL Cardiovascular : No unstable angina No prior congestive heart failure No prior myocardial infarction LVEF least 45 % MUGA echocardiogram Other : Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior trastuzumab No concurrent growth factor Chemotherapy : No prior anthracyclines No prior gemcitabine except prior low dose ( great 300 mg/m2/week ) gemcitabine radiotherapy At least 6 month since prior adjuvant therapy More 2 week since prior chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Chemotherapy More 2 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>